Table 2.
Patient characteristics.
| 5-AC-treated patients with multiple BM aspirations | |
|---|---|
| number of patients | 38 |
| age, median (range) | 70 (45-85) |
| male/female | 19/19 |
| WHO 2008 | |
| AML/MDS < 30% MB* | 5 |
| RAEB I | 9 |
| RAEB II | 18 |
| RCMD | 2 |
| CMML I | 1 |
| CMML II | 2 |
| MDS/MPN-u | 1 |
| IPSS risk group | |
| low | 0 |
| intermediate I | 9 |
| intermediate II | 20 |
| high | 4 |
| response to 5-AC therapy | |
| number of samples at each time point | |
| before therapy | 35 |
| After 4 cycles | 36 |
| After 8 cycles | 18 |
| Response as evaluated after 4thcycle | |
| number of responders | 20 |
| SD with HI | 2 |
| PR | 9 |
| CR | 2 |
| Cri | 7 |
| number of non-responders | 16 |
| SD without HI | 12 |
| PD |
4 |
|
MDS low risk group |
|
| number of patients | 35 |
| age at diagnosis, median (range) | 68 (46-83) |
| male/female | 9 / 26 |
| WHO 2008 | |
| MDS 5q | 10 |
| RCMD | 21 |
| MDS RN | 3 |
| MDS/MPN-u | 1 |
| IPSS risk group | |
| low | 35 |
| intermediate I | 0 |
| intemediate II | 0 |
| high |
0 |
|
AML sub-group |
|
| number of patients | 24 |
| age at diagnosis, median (range) | 73.5 (57-86) |
| male/female | 16/8 |
| WHO 2008 | |
| AML/MDS < 30% MB* | 12 |
| AML > 30% MB | 12 |
| IPSS risk group | |
| high | 12 |
| not applicable | 12 |
| Healthy donors | |
| number of donors | 8 |
| age at BM aspiration, median (range) | 39 (29-54) |
| male/female | 5 / 3 |